Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

3.14
-0.16 (-4.85%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :97,762
Date :05-29-2020

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

五月 5th, 2020|Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June已关闭评论

Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801 NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug [...]

Oramed Patent in Canada Allowed for Oral Delivery of Proteins

四月 7th, 2020|Oramed Patent in Canada Allowed for Oral Delivery of Proteins已关闭评论

NEW YORK, April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office [...]

Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19

四月 1st, 2020|Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19已关闭评论

- Oral insulin FDA End-of-Phase 2 meeting expected this quarter - Strong balance sheet with roughly $50M in cash - NASH intermediate study data expected this quarter NEW YORK, April 1, 2020 /PRNewswire/ -- Oramed Pharmaceuticals [...]

Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA

三月 19th, 2020|Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA已关闭评论

NEW YORK, March 19, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive feedback from its initial [...]